PennyPerformers.com: "Penny Stocks that Perform" picks are: BAX, MVSN, SNSS, TLAN

Jul 13, 2009 (M2 PRESSWIRE via COMTEX) -- TLAN | Quote | Chart | News | PowerRating -- Pennyperformers.com "Penny Stocks that Perform" picks are: Baxter International Inc. (NYSE: BAX), Macrovision Solutions Corporation (NASDAQ: MVSN), Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS), Talent Alliance, Inc. (PINKSHEETS: TLAN)

<< << <<

Sign-up for our FREE Stock Alerts AND NEWSLETTER at www.pennyperformers.com

<< << <<

Jul 13, 2009 -- Baxter International Inc. (NYSE: BAX | Quote | Chart | News | PowerRating) and Flamel Technologies, SA (NASDAQ: FLML) announced today that they have entered into agreement to formulate controlled release applications of blood clotting factor replacement therapies using Flamel's Medusa(R) Technology. The work between the two companies will focus on developing longer-acting formulations with the objective of reducing the frequency of infusions required to treat blood clotting disorders in hemophilia. Pursuant to the agreement between the two companies, Flamel will receive technology access fees totaling EUR 2.5 million. Baxter will pay all development costs for the program and have an exclusive right to negotiate a license to the Medusa platform.

"We continue to develop and advance novel therapies that improve patient convenience by decreasing the frequency of infusions to help people living with hemophilia lead a more normal life," said Hartmut J. Ehrlich, MD, vice president of global research and development in BioScience at Baxter. "We look forward to this partnership using Flamel's Medusa(R) Technology as a novel approach to address this goal."

"We are pleased to be working with Baxter to develop longer-acting formulations of factor replacement therapies for hemophilia patients," said Stephen H. Willard, Flamel's chief executive officer. "Baxter is an ideal partner for these molecules due to its extensive expertise in the field. Our work with Baxter allows us to leverage our expertise in drug delivery to create solutions for the administration of intravenous formulations of therapeutic proteins. This program has the potential to develop more convenient solutions for people living with hemophilia, their families, and physicians."

About Hemophilia

There are two types of hemophilia: hemophilia A (sometimes called classical hemophilia) and hemophilia B (sometimes called Christmas disease). Both are caused by a low level or absence of one of the proteins in the blood (called factors) that control bleeding. Hemophilia A is caused by a deficiency of factor VIII, and hemophilia B is caused by a deficiency of factor IX.

There is no difference between the two types of hemophilia, except that hemophilia B is about five times less common than hemophilia A. According to the World Federation of Hemophilia, more than 400,000 people in the world have hemophilia.

About Medusa

The Medusa platform uses biodegradable polymers to adsorb therapeutic large molecules through hydrophobic interaction, with no loss of bioactivity, for controlled release applications. The Medusa polymer is amphiphilic and spontaneously forms stable nanoparticles in water. They are robust over a wide range of pH values and can be stored as either stable liquid or stable dry forms that can be easily reconstituted in water.

About Flamel Technologies

Flamel Technologies, S.A. is a biopharmaceutical company principally engaged in the development of two unique polymer-based delivery technologies for medical applications. Flamel's Medusa technology is designed to deliver controlled-release formulations of therapeutic proteins and peptides and other molecules, without reduction in bioactivity. Micropump(R) is a controlled release and taste-masking technology for the oral administration of small molecule drugs; it is the intellectual platform licensed by GlaxoSmithKline for COREG CR(R).

About Baxter

Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.

<< << <<

Jul 13, 2009 -- Macrovision Solutions Corporation (NASDAQ: MVSN), a digital entertainment technology leader, today announced that CANAL+ Group, a leading pay-TV operator in France, has signed a multi-year licensing agreement for Macrovision's electronic program guide (EPG) patent portfolio.

CANAL+ Group joins pay-TV operators globally that are licensing Macrovision's technology under the NDS and Macrovision agreement (see NDS Joins Macrovision Patent Licensing Program) on EPG patents. The multi-year agreement allows CANAL+ Group to use Macrovision's licensed intellectual property in its EPGs deployed on its various platforms.

"This agreement is another important example of the value that our intellectual property brings to pay-TV operators and the subscribers they serve," said Samir Armaly, senior vice president, licensing, Macrovision. "CANAL+ Group joins a growing list of leading pay-TV operators worldwide that have elected to take a license under our EPG patent portfolio."

CANAL+ Group joins Macrovision's existing list of licensed pay-TV operators that include British Sky Broadcasting Limited, FOXTEL, Portugal Telecom, SKY Italia and UPC Broadband.

About CANAL+ Group

Canal+ Group is France's leading pay-TV operator and a major player in the programming and production of premium and special-interest channels, the broadcasting of pay-TV services, and a pioneer in the development of new television services. At year-end 2008, Canal+ Group had 10.6 million subscriptions to its different product offerings. CANAL+ Group runs pay-TV operations in Poland and in French-speaking countries around the world via Canal Overseas.

CANAL+ GROUP is also a European leader in the financing, acquisition and distribution of feature films through its affiliate StudioCanal.

About Macrovision Solutions Corporation

Macrovision Solutions Corporation is focused on powering the discovery and enjoyment of digital entertainment by providing a broad set of integrated solutions that are embedded in our customers' products and services and used by end consumers to simplify and guide their interaction with digital entertainment. Macrovision's technologies are deployed by companies in the entertainment, consumer electronics, cable and satellite, and online distribution markets to solve industry-specific challenges and bring greater value and a more robust user experience to their customers. The result of deploying Macrovision's solutions is a simple end user experience for discovering, managing and enjoying digital content. Macrovision provides interactive programming guides, connected middleware, media recognition, copy protection and rich media, data and metadata on music, games, movies and television programming.

<< << <<

Jul 13, 2009 -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS), a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers, today announced that it has received a $1.5 million milestone payment from Biogen Idec (Nasdaq: BIIB) for the selection of a Raf kinase inhibitor development candidate for the treatment of cancer. Biogen Idec is currently conducting IND-enabling GLP preclinical work with the Raf kinase development candidate.

"While our internal efforts are focused on the successful development of voreloxin, we are extremely pleased by the continued progress being made by Biogen Idec to advance a Raf kinase inhibitor toward the clinic," said Daniel Swisher, Sunesis' Chief Executive Officer.

In August 2004 the companies entered into a collaboration to discover and develop small molecule cancer therapeutics targeting kinases, a family of cell signaling enzymes that play a major role in the progression of cancer. The research term of this collaboration ended in June of 2008. Sunesis retains an option to participate in the co-development and co-promotion of the Raf kinase inhibitor resulting from this collaboration.

About Sunesis Pharmaceuticals

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing voreloxin in multiple indications to improve the lives of people with cancer.

<< << <<

Jul 10, 2009 -- Talent Alliance, Inc. (PINKSHEETS: TLAN | Quote | Chart | News | PowerRating) announced today that it has executed a Letter of Intent to jointly market its TalentExchange platform in China with one of China's leading recruitment firms, Global Talent. Through the partnership, the companies will bring together two cutting edge technologies into a single offering designed to improve efficiencies in the talent acquisition process, and jointly market and promote them in China.

"The partnership with Global Talent is a tremendous win for our business in China," said Brian Davis, CEO of Talent Alliance. "We have done much more that select a marketing partner; we entered into strategic relationship with one of the most progressive and forward thinking recruitment groups in China. We will bring together Global Talent's CloudATS and our TalentExchange products to offer a solution to employers and recruiters not currently available anywhere on the market. Global Talent brings with it a portfolio of large clients in China and we add this exclusive technology to the mix for a great potential channel for rapid expansion in China."

The ChinaTalentExchange(r) and Global Talent's CloudATS are both currently live and operating independently but will be brought together by a joint development process. The TalentExchange marketplace supports and greatly streamlines the hiring process for companies and improves the marketing and submission process for recruiters. ChinaTalentExchange is free to register and any fees associated with the successful hire of a candidate only occur on a contingency basis with a full money back guarantee to the employers.

About Talent Alliance:

Based in Austin, Texas and Shanghai, China -- Talent Alliance, Inc. provides talent management and talent acquisition technology applications and resources in the United States and The People's Republic of China. Talent Alliance provides world class permanent placement recruiting, contingent staffing, employee leasing and benefits management services, and proprietary talent acquisition technology solutions to small, medium sized businesses and multi-national corporations in the United States and the People's Republic of China. The company currently has offices in Texas, Florida, California, and Shanghai and Beijing, China.

<< << <<

About PennyPerformers.com

PennyPerformers.com has become one of the premier stops for investors who wish to experience huge profits via investing in up-and-coming publicly traded companies.

Penny Performers email report service is free to those investors who sign up on our website. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to OTCBB and Pinksheet companies that have the potential of showing increased activity and Standing Out from the rest of the market. To subscribe to this free service, visit the Penny Performers Report home page at www.PennyPerformers.com and select the "join now" button.

Join us at www.PennyPerformers.com for a complimentary subscription to the most exciting online financial newsletter on the market.

Disclaimer: Verify all claims and do your own due diligence. PennyPerformers.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyPerformers.com is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. PennyPerformers.com is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b), PennyPerformers.com is owned and operated by PennyPerformers.com. Neither PennyPerformers.com nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this e-mail, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since PennyPerformers.com receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in PennyPerformers.com statements and opinions and such statements and opinions cannot be considered independent. PennyPerformers.com and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. PennyPerformers.com services are often paid for using free-trading shares. PennyPerformers.com may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.

Visit us for a full Disclaimer at: www.PennyPerformers.com/disclaimer.htm

CONTACT: Jason A. Hilton, Penny Performers Tel: +1 866 704 0122 e-mail: Jason@Newmediaadvisorsllc.com e-mail: info@standoutstocks.com

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index